Abstract: Methods are provided for close-range intraoperative, endoscopic and intravascular detection and treatment of lesions, including tumors and non-malignant lesions. The methods use antibody fragments or subfragments labeled with isotopic and non-isotopic agents. Also provided are methods for detection and treatment of lesions with photodynamic agents and methods of treating lesions with a protein conjugated to an agent capable of being activated to emit Auger electron or other ionizing radiation. Compositions and kits useful in the above methods are also provided.

Abstract: Provided are methods and compositions for detecting and treating normal, hypoplastic, ectopic or remnant tissue, organ or cells in a mammal. The method comprises parenterally injecting a mammalian subject, at a locus and by a route providing access to said tissue or organ, with an composition comprising antibody/fragment which specifically binds to targeted organ, tissue or cell. The antibody/fragment may be administered alone, or labeled or conjugated with an imaging, therapeutic, cytoprotective or activating agent.

Abstract: Anticancer, antimicrobial and autoimmune disease, and anti-organ rejection therapy using cytotoxic agents is improved using cytokines to prevent, mitigate or reverse adverse radiation-induced or drug-induced toxicity, especially to hematopoietic cells. Cytotoxic agents can include radioisotopes, drugs, toxins and even unconjugated cytotoxic antibodies. A preferred cytokine is IL-1. Higher doses of cytotoxic agents can be administered and tolerated by the patient and dose-limiting marrow toxicity can be prevented, palliated or reversed using adjunct cytokine therapy.

Abstract: A polyspecific anti-leukocyte antibody conjugate for targeting foci of leukocyte accretion comprises an immunoreactive polyspecific composite of at least two different substantially monospecific antibodies or antibody fragments, conjugated to at least one imaging agent, wherein at least two of said antibodies or antibody fragments specifically bind to different leukocyte cell types.A method for targeting an imaging agent to an inflammatory or infectious lesion comprises injecting a mammal parenterally with an effective amount for targeting of the above anti-leukocyte imaging conjugate.A therapeutic anti-leukocyte antibody-agent conjugate for targeting foci of leukocyte accretion comprises at least one immunoreactive substantially monospecific antibody or antibody fragment which specifically binds to at least one leukocyte cell type, conjugated to at least one therapeutic antimicrobial agent and/or radionuclide.

Abstract: Anticancer, antimicrobial and autoimmune disease, and anti-organ rejection therapy using cytotoxic agents is improved using cytokines to prevent, mitigate or reverse adverse radiation-induced or drug-induced toxicity, especially to hemotopoietic cells. Cytotoxic agents can include radioisotopes, drugs, toxins and even unconjugated cytotoxic antibodies. A preferred cytokine is IL-1. Higher doses of cytotoxic agents can be administered and tolerated by the patient and dose-limiting marrow toxicity can be prevented, palliated or reversed using adjunct cytokine therapy.

Abstract: An improved method for lymphoscintigraphy or magnetic resonance lymphography involves subtraction of a negative image produced using a gross imaging agent from a positive image produced with a specific antibody imaging agent. Another embodiment of the invention uses an antibody to lymphatic tissue as an imaging agent for lymphatics. A further embodiment uses a magnetic resonance image enhancing agent for magnetic resonance lymphography.Reagents and kits for use in the foregoing method are also provided.

Abstract: The present invention relates to conjugates of diagnostic or therapeutic principles, such as drugs, toxins, chelators, boron compounds and detectable labels, to an antibody, in which the diagnostic or therapeutic principle is first loaded onto a polymer carrier such as an aminodextran or a polypeptide of at least 50 amino acids in length, and this intermediate is in turn site-specifically conjugated to a targeting antibody such as an antitumor antibody. The resultant conjugate substantially retains the immunoreactivity of the antibody, and targets the diagnostic or therapeutic principle to a target tissue or organ where the diagnostic or therapeutic effect is realized.

Abstract: Methods are provided for short-range intraoperative and endoscopic detection and therapy of tumors using radiolabeled antibodies and, in some cases, techniques for reducing or correcting for non-specific background radiation to improve resolution. Therapy using external radiation and/or laser or mechanical endoscopically introduced tumor removal means can be combined with the detection methods to increase precision of the tumor removal operations.

Abstract: A polyspecific anti-leukocyte antibody conjugate for targeting foci of leukocyte accretion comprises an immunoreactive polyspecific composite of at least two different substantially monospecific antibodies or antibody fragments, conjugated to at least one imaging agent, wherein at least two of said antibodies or antibody fragments specifically bind to different leukocyte cell types.A method for targeting an imaging agent to an inflammatory or infectious lesion comprises injecting a mammal parenterally with an effective amount for targeting of the above anti-leukocyte imaging conjugate.A therapeutic anti-leukocyte antibody-agent conjugate for targeting foci of leukocyte accretion comprises at least one immunoreactive substantially monospecific antibody or antibody fragment which specifically binds to at least one leukocyte cell type, conjugated to at least one therapeutic antimicrobial agent.

Abstract: Antibodies specific to specific CEA epitopes and epitopes of CEA-cross-reactive antigens are provided. Methods of use of these antibodies and purified CEA antigens and cross-reactive antigens are also provided.

Abstract: A conjugate of methotrexate to an antibody is prepared by loading methotrexate onto an aminodextran, then specifically conjugating the polymer carrier to the carbohydrate portion of an antitumor antibody, using a reduced Schiff base linkage. The conjugate is useful for tumor targeted therapy.

Abstract: A method for enhancing target specificity of antibody localization comprises injecting a second antibody specific to a labeled target-specific antibody to reduce the level of non-targeted circulating specific antibody, thereby increasing the localization ratio. The foregoing method is useful for imaging tumors and infectious lesions, and for therapy.

Abstract: A tryptic peptide is produced by partial tryptic digestion of purified, high molecular size colon-specific antigen-p (CSAp), to produce a lower molecular size antigen carrying the CSAp antigenic determinant. The tryptic peptide is used to produce monospecific anti-CSAp antibodies.

Abstract: Methods are provided for using radiolabeled antibodies specific to intracellular tumor-associated markers for detection, localization and therapy of tumors. Antibodies and injectable compositions for use in the methods of the invention are also provided.

Abstract: Improved methods are provided for using radiolabeled antibodies to tumor cell surface antigens to locate, diagnose and stage tumors having such antigens on their cell surfaces by external photoscanning, whereby significantly increased resolution, convenience and/or efficiency of operation may be achieved. A method is provided for using highly specific radiolabeled antibodies to cell surface antigens for tumor therapy. Radiolabeled antibodies and injectable compositions containing them are provided for use in the method of the invention.

Abstract: Methods are provided for using radiolabeled antibodies specific to intracellular tumor-associated markers for detection, locatization and therapy of tumors. Antibodies and injectable compositions for use in the methods of the invention are also provided.

Abstract: Improved methods are provided for using radiolabeled antibodies to carcinoembronic antigen (CEA) to locate, diagnose and stage CEA-containing tumors by external photoscanning, whereby significantly increased resolution, convenience and/or efficiency of operation may be achieved. A method is provided for using highly specific radiolabeled anti-CEA antibodies for tumor therapy. An injectable composition and radiolabeled antibodies are provided for use in the method of the invention.

Abstract: Methods are provided for using radiolabeled antibody fragments specific to tumor-associated markers for detection, localization and therapy of tumors. Mixtures of labeled fragments with varied specificity or multivalent hybrid fragments permit detection and localization of more than one tumor or tumor cell type. Antibodies and injectable compositions for use in the methods of the invention are also provided.